(Total Views: 557)
Posted On: 06/17/2021 11:39:03 AM
Post# of 148903
It's another drug, but a Brazilian Albert Einstein Covid study just made NEJM:
https://www.medpagetoday.com/infectiousdiseas...ate_active
Same principal investigator as ours.
In this study, Xeljanz, a JAK inhibitor, decreased high-flow oxygen (non-intubated) patients' "death or respiratory failure" from 29% to 18%.
https://www.medpagetoday.com/infectiousdiseas...ate_active
Same principal investigator as ours.
In this study, Xeljanz, a JAK inhibitor, decreased high-flow oxygen (non-intubated) patients' "death or respiratory failure" from 29% to 18%.
(6)
(0)Scroll down for more posts ▼
